8-K

================================================================================

                UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    Form 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

                                 January 4, 2005
                Date of Report (Date of Earliest Event Reported):

                                  ABAXIS, Inc.
             (Exact name of registrant as specified in its charter)

          California                      000-19720              77-0213001
(State or other Jurisdiction of   (Commission File Number)    (I.R.S. Employer)
        Incorporation)                                       Identification No.)

                                3240 Whipple Road
                              Union City, CA 94587
          (Address of principal executive offices, including zip code)

                                 (510) 675-6500
              (Registrant's telephone number, including area code)

     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities Act
     (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
     (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

================================================================================



ITEM 8.01 OTHER EVENTS.

On January 4, 2005, Abaxis, Inc., announced today changes in its domestic sales
and marketing structure and management leadership team with the goal of
providing increased management focus in both the veterinarian and medical
markets and to accelerate growth. A copy of the press release is attached hereto
as Exhibit 99.1.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

        (c)      EXHIBITS.

        The following exhibit is furnished with this report on Form 8-K:

        Exhibit No.       Description
        -----------       -----------------------------------
        99.1              Press release dated January 4, 2005

                                        2


                                   SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:  January 4, 2005

                                                Abaxis, Inc.

                                                By: /s/ Alberto Santa Ines
                                                    ---------------------------
                                                    Alberto Santa Ines
                                                    Vice President, Finance and
                                                    Chief Financial Officer
                                                    Chief Financial Officer

                                        3

EX-99.1

                                                                    Exhibit 99.1

             ABAXIS CHANGES SALES AND MARKETING MANAGEMENT STRUCTURE

    UNION CITY, Calif., Jan. 4 /PRNewswire-FirstCall/ -- Abaxis, Inc.
(Nasdaq: ABAX), a medical products company manufacturing point-of-care blood
analysis systems, announced changes in its domestic sales and marketing
structure and management leadership team with the goal of providing increased
management focus in both the veterinarian and medical markets and to
accelerate growth.

    Richard Schoen, VP of Domestic Sales and Marketing for both the veterinary
and medical markets is resigning as of January 5, 2005. The Company will divide
sales and marketing responsibilities along veterinary and medical market lines
and will hire a vice president of sales and marketing for each segment. This new
structure will allow enhanced optimization of marketing and sales resources in
each segment with the goal of better forecasting capabilities, increased sales
and earnings growth.

    Clint Severson, chairman and CEO of Abaxis, commented, "All of us at Abaxis
want to thank Rich for his contributions to Abaxis over the last two years. Over
that time domestic sales have grown 53 percent. We wish Rich the best for the
future."

    The Company today announced the promotion of Martin Mulroy to National
Director, Veterinary Sales. Mr. Mulroy joined Abaxis in November 1997 as a
regional sales manager. In 1999 he was promoted to Eastern Area Sales Director.
Reporting to Mr. Mulroy will be four area sales directors and up to twenty-eight
regional sales managers. Mr. Mulroy and his team will report directly to Mr.
Severson until a veterinary vice president of Sales and Marketing is named.

    Richard Duncan has been appointed Director of Sales for the Piccolo market.
Mr. Duncan previously held the position of Business Development Manager for
Urologix of Minneapolis, Minnesota. Prior to Urologix, Mr. Duncan served in
various sales and management positions at Physician Sales and Service
Corporation from 1993 to 2002, ending as Northern Regional Vice President from
2000 to 2002. Mr. Duncan and his team will report to Abaxis vice president and
chief operations officer, Bob Milder, until a medical market vice president of
Sales and Marketing is named.

    The Company also announced that preliminary figures indicate that sales for
the quarter ended December 31, 2004 exceeded the internal sales goal set prior
to the beginning of the quarter. Management believes that the transition away
from the VEDCO co-op has yielded better than anticipated results during the
quarter. The Company expects total revenues for the quarter ended December 31,
2004 to be in the upper range of $10.5 million to $12.0 million.

    About Abaxis
    ABAXIS develops, manufactures and markets portable blood analysis systems
for use in any patient-care setting to provide clinicians with rapid blood
constituent measurements. The system consists of a compact, 6.9 kilogram,
portable analyzer and a series of 8-cm diameter single-use plastic disks, called
rotors or reagent discs that contain all the reagents necessary to perform a
fixed menu of tests. The system can be operated with minimal training and
perform multiple tests on whole blood using either venous or fingerstick
samples. The system provides test results in less than 14 minutes with the
precision and accuracy equivalent to a clinical laboratory.



    Special Note Regarding Forward-Looking Statements
    This press release includes statements that constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995 (the "Reform Act"). ABAXIS claims the protection of the safe-harbor for
forward-looking statements contained in the Reform Act. Specific forward-
looking statements contained in this press release include, but are not limited
to, risks and uncertainties related to quarter three net product sales and
earnings per shares estimates as a result of ending our relationship with VEDCO,
the market acceptance of the Company's products and the continuing development
of its products, risks associated with manufacturing and distributing its
products on a commercial scale, risks associated with entering the human
diagnostic market on a larger scale, risks involved in carrying of inventory,
risks from unexpected problems or delays in the Company's manufacturing
facility, risks associated with the ability to attract and retain competent
sales personnel, general market conditions, competition, risks and uncertainties
related to its ability to raise capital in order to fund its operations and
other risks detailed from time to time in ABAXIS' periodic reports filed with
the United States Securities and Exchange Commission. Forward-looking statements
speak only as of the date the statement was made. ABAXIS does not undertake and
specifically disclaims any obligation to update any forward-looking statements.

SOURCE  Abaxis, Inc.
    -0-                             01/04/2005
    /CONTACT:  Clint Severson, Chief Executive Officer of ABAXIS, Inc.,
+1-510-675-6500; or Joe Dorame, Joe Diaz, or Robert Blum, all of RCG Capital
Markets Group, +1-480-675-0400/
    /Web site:  http://www.abaxis.com /
_